Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Medica (Italy) · Vita-Salute San Raffaele University · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,348
total citations
- FWCI
- 61.46
- Percentile
- 100%
- References
- 33
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Pertuzumab
- Trastuzumab
- Docetaxel
- Medicine
- Internal medicine
- Clinical endpoint
- Breast cancer
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.